PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer

PD-1 and LAG-3 dual blockade: emerging mechanisms and potential therapeutic prospects in cancer

Saved in:

Bibliographic Details
Main Authors:	Xiangyu Qiu, Zhaoan Yu, Xiaoqing Lu, Xin Jin, Jinrong Zhu, Rongxin Zhang
Format:	Article
Language:	English
Published:	China Anti-Cancer Association 2024-11-01
Series:	Cancer Biology & Medicine
Online Access:	https://www.cancerbiomed.org/content/21/11/970
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti‐Lag‐3 via reducing FGL1 expression
by: Jianchu Wang, et al.
Published: (2020-10-01)

Therapeutic potential of targeting LAG-3 in cancer
by: Diwakar Davar, et al.
Published: (2025-07-01)

Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
by: Peng Gao, et al.
Published: (2025-08-01)

Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity
by: Yoichiro Narikawa, et al.
Published: (2025-08-01)

Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer
by: Zong Sheng Guo, et al.
Published: (2020-05-01)

Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
by: Ting Chen, et al.
Published: (2024-07-01)

Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging
by: Zhen Quan, et al.
Published: (2025-08-01)

Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial
by: David Hsiehchen, et al.
Published: (2025-07-01)

Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8+ T cells
by: Susan N Christo, et al.
Published: (2024-01-01)

CTLA-4 and PD-1 combined blockade therapy for malignant melanoma brain metastases: mechanisms, challenges, and prospects
by: Jia-Wen Wang, et al.
Published: (2025-07-01)

Basic rules to respond to PD-1 blockade cancer immunotherapy
by: Antoni Ribas
Published: (2025-05-01)

Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1/PD-L1 blockades in NSCLC: a prospective exploratory study
by: Yuan Gao, et al.
Published: (2025-07-01)

Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion
by: Qinpei Cheng, et al.
Published: (2025-05-01)

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
by: Chenyu Mao, et al.
Published: (2024-12-01)

Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy
by: Louis Boon, et al.
Published: (2020-10-01)

Pathological mechanisms and advances in neoadjuvant PD-1 blockade combined with chemotherapy for head and neck cancer
by: Yun-jing Hou, et al.
Published: (2024-12-01)

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
by: Megan Schollenberger, et al.
Published: (2017-08-01)

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1
by: Bar Kaufman, et al.
Published: (2025-05-01)

SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma
by: Da Huang, et al.
Published: (2025-06-01)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
by: Tuba N. Gide, et al.
Published: (2023-12-01)

DON‐Loaded Nanodrug‐T Cell Conjugates With PD‐L1 Blockade for Solid Tumor Therapy
by: Xin Yang, et al.
Published: (2025-07-01)

IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade
by: Yoshiya Ohno, et al.
Published: (2025-03-01)

IL-2 and IL-15 augment HBV therapeutic vaccination and PD1 blockade for functional cure in the AAV-HBV mouse model
by: Gavin Lewis, et al.
Published: (2025-07-01)

Potential Use of Interleukin-10 Blockade as a Therapeutic Strategy in Human Cutaneous Leishmaniasis
by: Lucio Roberto Castellano, et al.
Published: (2015-01-01)

PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
by: Abul Azad, et al.
Published: (2016-12-01)

PD-1 Blockade with Nivolumab as a New Immunotherapy for Classical Hodgkin’s Lymphoma
by: EA Demina
Published: (2018-07-01)

Deciphering the mechanisms of long non-coding RNAs in ferroptosis: insights into its clinical significance in cancer progression and immunology
by: Shengming Ou, et al.
Published: (2025-01-01)

Downregulation of PD-L1 expression by Wnt pathway inhibition to enhance PD-1 blockade efficacy in hepatocellular carcinoma
by: Yu-Yun Shao, et al.
Published: (2025-04-01)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
by: Miren Zuazo, et al.
Published: (2019-06-01)

The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade
by: Yuchen Zhang, et al.
Published: (2024-11-01)

Targeting CD39 boosts PD-1 blockade antitumor therapeutic efficacy via strengthening CD8 + TILs function and recruiting B cells in cervical cancer
by: Lili Jiang, et al.
Published: (2025-06-01)

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
by: Meng Zhang, et al.
Published: (2022-03-01)

TRPV1 inhibition sensitizes tumors to PD-1 blockade by reversing resistance to CTL-mediated killing
by: Min Kyu Son, et al.
Published: (2025-07-01)

PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia
by: O. N. Selyutina, et al.
Published: (2023-12-01)

Synergistic PD‐1/LAG‐3 Inhibition: Mechanistic Insights and Implications for Enhanced Tumor Immunotherapy
by: Jianqiao Shentu, et al.
Published: (2025-06-01)

Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade
by: Nina B. Curkovic, et al.
Published: (2025-12-01)

Dexmedetomidine induces immunogenic cancer cell death and sensitizes tumors to PD-1 blockade
by: Peng Liu, et al.
Published: (2025-06-01)

Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study
by: Shintaro Iwama, et al.
Published: (2025-06-01)

Potential‐Driven Dynamic Spring‐Effect of Pd─Cu Dual‐Atoms Empowered Stability and Activity for Electrocatalytic Reduction
by: Pei‐Hua Li, et al.
Published: (2025-07-01)

Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects
by: Maria Jure-Kunkel, et al.
Published: (2025-04-01)